Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26532556 | 0.90 | CYP11B2 (0.43) | GRM5CYP11B1CYP11B2CTSKABL1 | |
| SCHEMBL26555707 | 0.80 | CTSK (0.40) | CYP11B1CYP11B2CTSKABL1MAPK14 | |
| SCHEMBL26532564 | 0.77 | CTSS (0.40) | CYP11B1CYP11B2CTSKABL1 | |
| SCHEMBL19454850 | 0.77 | LDHA (0.47) | CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL26532553 | 0.76 | ABL1 (0.43) | GRM5ABL1CYP1A2CYP3A4MAPK14 | |
| SCHEMBL26532558 | 0.74 | RXRA (0.38) | ABL1CYP1A2MAPK14 | |
| SCHEMBL22080310 | 0.74 | NPC1 (0.53) | CTSK | |
| SCHEMBL26532566 | 0.73 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP1A2ALDH1A1 | |
| SCHEMBL26532554 | 0.72 | ALOX5AP (0.40) | ABL1CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL26627039 | 0.72 | NPC1 (0.36) | ABL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230138288-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138288-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, RUVBL2, LBR | GRM5 2153/4885CYP11B1 1121/4885CYP11B2 702/4885 |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, L1CAM, OPRM1 | GRM5 3314/4885CYP11B1 2335/4885CYP11B2 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.